ImmunoGen Inc (IMGN) Stock Price, Quote, News and Overview
NASDAQ:IMGN - Nasdaq - US45253H1014 - Common Stock - Currency: USD
IMGN Quote, Performance and Key Statistics
31.23
0 (0%)
The current stock price of IMGN is 31.23 USD. In the past month the price increased by 5.15%. In the past year, price increased by 617.93%.
IMGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IMGN
Company Profile
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. The company is headquartered in Waltham, Massachusetts and currently employs 277 full-time employees. The firm is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The firm is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Company Info
ImmunoGen Inc
830 Winter Street
Waltham MASSACHUSETTS 02451 US
CEO: Mark J. Enyedy
Employees: 277
Company Website: https://www.immunogen.com/
Phone: 17818950600
ImmunoGen Inc / IMGN FAQ
What is the stock price of ImmunoGen Inc today?
The current stock price of IMGN is 31.23 USD.
What is the ticker symbol for ImmunoGen Inc stock?
The exchange symbol of ImmunoGen Inc is IMGN and it is listed on the Nasdaq exchange.
On which exchange is IMGN stock listed?
IMGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ImmunoGen Inc stock?
19 analysts have analysed IMGN and the average price target is 31.69 USD. This implies a price increase of 1.46% is expected in the next year compared to the current price of 31.23. Check the ImmunoGen Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ImmunoGen Inc worth?
ImmunoGen Inc (IMGN) has a market capitalization of 8.72B USD. This makes IMGN a Mid Cap stock.
How many employees does ImmunoGen Inc have?
ImmunoGen Inc (IMGN) currently has 277 employees.
What are the support and resistance levels for ImmunoGen Inc (IMGN) stock?
ImmunoGen Inc (IMGN) has a support level at 29.76. Check the full technical report for a detailed analysis of IMGN support and resistance levels.
Is ImmunoGen Inc (IMGN) expected to grow?
The Revenue of ImmunoGen Inc (IMGN) is expected to grow by 344.16% in the next year. Check the estimates tab for more information on the IMGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ImmunoGen Inc (IMGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMGN, evaluating the profitability, health, valuation and growth aspects
- ImmunoGen Inc (IMGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ImmunoGen Inc (IMGN) Sales and EPS estimates to see what analysts future expectations are.
- ImmunoGen Inc (IMGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ImmunoGen Inc (IMGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ImmunoGen Inc (IMGN) Stock Chart to make your own analysis
- ImmunoGen Inc (IMGN) Latest news and press-releases to stay up to date.
Does ImmunoGen Inc (IMGN) stock pay dividends?
IMGN does not pay a dividend.
When does ImmunoGen Inc (IMGN) report earnings?
ImmunoGen Inc (IMGN) will report earnings on 2024-04-26, after the market close.
What is the Price/Earnings (PE) ratio of ImmunoGen Inc (IMGN)?
ImmunoGen Inc (IMGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
IMGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IMGN. When comparing the yearly performance of all stocks, IMGN is one of the better performing stocks in the market, outperforming 99.75% of all stocks.
IMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMGN. While IMGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMGN Financial Highlights
Over the last trailing twelve months IMGN reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 62.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.94% | ||
| ROE | -13.09% | ||
| Debt/Equity | 0.16 |
IMGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 71% to IMGN. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 108.78% and a revenue growth 344.16% for IMGN